Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230
about
HIV-1 drug resistance and resistance testing.Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western IndiaAssessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, MalawiRaltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority studyProtease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
P2860
Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Lopinavir/Ritonavir Monotherap ...... ical Trials Group (ACTG) A5230
@ast
Lopinavir/Ritonavir Monotherap ...... ical Trials Group (ACTG) A5230
@en
type
label
Lopinavir/Ritonavir Monotherap ...... ical Trials Group (ACTG) A5230
@ast
Lopinavir/Ritonavir Monotherap ...... ical Trials Group (ACTG) A5230
@en
prefLabel
Lopinavir/Ritonavir Monotherap ...... ical Trials Group (ACTG) A5230
@ast
Lopinavir/Ritonavir Monotherap ...... ical Trials Group (ACTG) A5230
@en
P2093
P2860
P356
P1476
Lopinavir/Ritonavir Monotherap ...... ical Trials Group (ACTG) A5230
@en
P2093
Carole L Wallis
David A Katzenstein
Evgenia Aga
Heather J Ribaudo
John A Bartlett
John A Crump
Karin L Klingman
Khuanchai Supparatpinyo
Michael R Norton
Mina C Hosseinipour
P2860
P304
P356
10.1093/CID/CIV109
P407
P577
2015-02-18T00:00:00Z